SCHEMBL3564003

SCHEMBL3564003

Cc1ccccc1C(C(=O)Nc1ccc(N(C)c2ccncc2)cc1)N(C(N)=O)c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.39
ALDH1A1 P00352 4/20 0.38
GAA P10253 4/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ROCK2 O75116 1/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 3/20 0.38
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
THRB P10828 1/20 0.36
RAF1 P04049 1/20 0.36
TYK2 P29597 2/20 0.35
LTA4H P09960 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NT5E P21589 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5813906 0.87 ALDH1A1 (0.44) ALDH1A1GAAKDM4EMAPTTDP1
SCHEMBL3564007 0.80 KMT2A (0.44) FFAR2GAAKDM4EMAPTKMT2A
SCHEMBL3557259 0.80 HDAC4 (0.44) FFAR2ALDH1A1GAAKDM4EMAPT
SCHEMBL3559106 0.79 F10 (0.43) ALDH1A1GAAKDM4EMAPTTDP1
SCHEMBL3559217 0.79 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL3568352 0.78 F10 (0.42) ALDH1A1GAAKDM4EMAPTTDP1
SCHEMBL3562244 0.78 PCTP (0.35) ALDH1A1GAAKDM4EMAPTTDP1
SCHEMBL3557436 0.78 PPARG (0.38) ALDH1A1MAPTRAB9ANPC1
SCHEMBL3557869 0.76 EP300 (0.46) ALDH1A1GAAKDM4EMAPTTDP1
SCHEMBL3563838 0.75 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 FFAR2 2315/4885ALDH1A1 1143/4885GAA 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.